The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Prevalence of frailty in community-dwelling older persons: a systematic review
Collard, R. M., Boter, H., Schoevers, R. A., & Oude Voshaar, R. C. (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.04054.x · Cited by 3,073
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560 · cited 2×
“This approval was based on the results of the phase II KarMMa trial 116 , in which 128 patients who had received three or more lines of therapy, including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody, were treated with ide-cel.”
Self-citationPalumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210
Self-citationBerdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756 · cited 2×
“This approval was supported by the results from the pivotal phase I/II CARTITUDE-1 trial 114,115 , which involved 113 patients who had received a median of six prior lines of therapy (range three to 18) including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody.”
Teclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269 · cited 2×
“%) and neurotoxicity (14.5%, including ICANS in 3.0%, all of grade 1–2) 119,120 .”
InfluentialSelf-citationDaratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045 · cited 1×
“DaraRd 72 , DaraVM plus prednisone 73 and VRd 74 are the SOC regimens previously recommended by the EHA 11,12 for the treatment of transplant-ineligible patients with NDMM.”
Self-citationSantomasso, B. D., Park, J. H., Salloum, D., Riviere, I., Flynn, J., Mead, E., Halton, E., Wang, X., Senechal, B., Purdon, T., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1319 · Cited by 942
Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908
Metadata
- Authors
- Dimopoulos, M. A., Terpos, E., Boccadoro, M., Moreau, P., Mateos, M.-V., Zweegman, S., Cook, G., Engelhardt, M., Delforge, M., Hajek, R., Schjesvold, F., Gay, F., Manier, S., Weisel, K. C., Kaiser, M., van de Donk, N. W. C. J., Zamagni, E., Rodriguez-Otero, P., Perrot, A., Driessen, C., Bila, J., Laane, E., Dytfeld, D., Touzeau, C., Beksac, M., Raab, M. S., Cavo, M., Mohty, M., Spencer, A., Ludwig, H., Einsele, H., San-Miguel, J., & Sonneveld, P.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2025-07-07
- Volume
- 22
- Issue
- 9
- Pages
- 680-700
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W4412070200
- Cited by
- 165
- References
- 29
- FWCI
- 46.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. https://app.cochat.ai/papers/10.1038/s41571-025-01041-x
- The paper
- Dimopoulos, M. A., Terpos, E., Boccadoro, M., Moreau, P., Mateos, M.-V., Zweegman, S., Cook, G., Engelhardt, M., Delforge, M., Hajek, R., Schjesvold, F., Gay, F., Manier, S., Weisel, K. C., Kaiser, M., van de Donk, N. W. C. J., Zamagni, E., Rodriguez-Otero, P., Perrot, A., . . . Sonneveld, P. (2025). EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-025-01041-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.